1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma : 12/01/2022 Mayne Pharma adds a generic PROTOPIC to US portfolio

01/11/2022 | 06:38pm EDT

ASX Announcement

MAYNE PHARMA ADDS GENERIC PROTOPIC® TO US

DERMATOLOGY PORTFOLIO

12 January 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of tacrolimus ointment, 0.1% in the United States.

Tacrolimus ointment is a generic version of PROTOPIC®, indicated for the treatment of atopic dermatitis. According to IQVIA, the annual US market sales for tacrolimus ointment were US$80 million for the twelve months ending November 20211.

Mayne Pharma entered into a license and supply agreement with Sandoz AG to distribute tacrolimus ointment in non-retail channels.

Mayne Pharma's CEO Scott Richards said, "We are pleased to partner with Sandoz, a global leader in generic pharmaceuticals and biosimilars. Mayne Pharma has launched nine dermatology products in FY22 targeting markets with IQVIA sales of more than US$380 million1."

"Mayne Pharma's US portfolio of brand and generic products covers 9 of the top 15 most prescribed molecules by dermatologists and treat a range of dermatological conditions. We continue to have active discussions with other parties around further product collaborations that will continue to add breadth to our portfolio to satisfy the needs of dermatologists and patients."

For further information contact:

Lisa Pendlebury (VP Investor Relations & Communications) +61 419 548 434, lisa.pendlebury@maynepharma.com

Authorised for release to the ASX by the Chair.

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world.

1 IQVIA, MAT Sales, November 2021

ASX Announcement

Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.

PROTOPIC® is a registered trademark of a third party.

Page 2

Disclaimer

Mayne Pharma Group Limited published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2022 23:37:06 UTC.


© Publicnow 2022
All news about MAYNE PHARMA GROUP LIMITED
05/09Mayne pharma announced as recipient of $4.8m federal government grant
AQ
05/09Mayne Pharma Group Secures $3.4 Million Manufacturing Grant
MT
03/22Mayne Pharma Group Limited - NON-EXECUTIVE DIRECTOR APPOINTMENT
AQ
03/21MAYNE PHARMA : 22/03/2022 Non Executive Director Appointment
PU
03/21Ann Custin Accepts to Join the Board and Audit and Risk Committee of Mayne Pharma Group..
CI
03/20MAYNE PHARMA GROUP LIMITED(ASX : MYX) added to S&P/ASX Emerging Companies Index
CI
02/28Mayne pharma reports 1hfy22 results
AQ
02/25Mayne Pharma Group Narrows Loss in Six Monts to December 2021
MT
02/24TRANSCRIPT : Mayne Pharma Group Limited, H1 2022 Earnings Call, Feb 24, 2022
CI
02/24MAYNE PHARMA : 2022 Half Year Investor Presentation
PU
More news
Financials
Sales 2022 403 M 285 M 285 M
Net income 2022 -75,3 M -53,3 M -53,3 M
Net Debt 2022 271 M 191 M 191 M
P/E ratio 2022 -6,38x
Yield 2022 -
Capitalization 529 M 375 M 375 M
EV / Sales 2022 1,98x
EV / Sales 2023 1,73x
Nbr of Employees 967
Free-Float 77,3%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,30 AUD
Average target price 0,36 AUD
Spread / Average Target 19,2%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Frank C. Condella Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development